Molecular biology reports · 2026
Brief report: Therapeutic benefit of ISA-2011B in colorectal cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hanitrarimalala Veroniaina, Persson Jenny, Wingren Anette Gjörloff
Аннотация
UNLABELLED: ISA-2011B is a phosphatidylinositol-4-phosphate 5-kinase-α (PIP5K1α) inhibitor that has been reported to be selective in suppressing the growth of prostate, breast and hepatic cancer cells. Here, cell viability of 2-dimensional (2D) cultures and 3-dimensional (3D) spheroids of four colorectal cancer (CRC) cell lines with different mutations were evaluated after treatment with the drug ISA-2011B.
METHODS: The CRC cell lines were investigated for viability in 2D and 3D spheroid cultures. The 3D spheroids were subjected to imaging, and the average volumes were measured.
RESULTS: The results show different treatment effects of ISA-2011B on the four CRC cell lines, indicating that mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol 3-kinase (PI3K) genes can play a role in the outcome of treatment.
CONCLUSIONS: With additional studies, we suggest that ISA-2011B can be a promising drug target in CRC.
METHODS: The CRC cell lines were investigated for viability in 2D and 3D spheroid cultures. The 3D spheroids were subjected to imaging, and the average volumes were measured.
RESULTS: The results show different treatment effects of ISA-2011B on the four CRC cell lines, indicating that mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol 3-kinase (PI3K) genes can play a role in the outcome of treatment.
CONCLUSIONS: With additional studies, we suggest that ISA-2011B can be a promising drug target in CRC.